Trials / Terminated
TerminatedNCT01006785
Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer
Phase II Clinical Study: A Randomized, Open, and Dose Ranging Study to Evaluate the Efficacy and Safety of DLBS1425 in Subjects With Metastatic / Advanced Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Dexa Medica Group · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are : * to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and * to determine the minimal effective and safe dose of DLBS1425 in the therapy of advanced/metastatic breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DLBS1425 | 3 X 150 mg daily for 12 - 16 weeks of treatment |
| DRUG | DLBS1425 | 3 X 300 mg daily for 12 - 16 weeks of treatment |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2009-11-03
- Last updated
- 2012-10-18
Locations
3 sites across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT01006785. Inclusion in this directory is not an endorsement.